1. What data in particular will be shared?
   Response - All of the individual participant data collected during the trial, after de-identification.
   


2. What additional supporting information will be shared?
   Response -  Study Protocol
   Response -  Statistical Analysis Plan
   Response - Informed Consent Form
   Response - Clinical Study Report
   
   
3. Who will be able to view these files?
   Response - Anyone
   


4. For what types of analyses will this data be available?
   Response - Any purpose.
   


5. By what mechanism will data be made available?
   Response - Data are available indefinitely at (Link to be included www.hyperuricemia.in).
   


6. For how long will this data be available start date provided 01-04-2026 and end date provided 01-04-2031?
   Response - Beginning 3 months and ending 5 years following article publication.
   


7. Any URL or additional information regarding plan/policy for sharing IPD? 
   Additional Information - nil

Hyperuricemia is defined as a serum urate concentration of >6.8mg /dl for men and >5.7mg/dl for women. Worldwide, the prevalence of hyperuricemia has increased substantially in recent decades. The most well-known disease induced by hyperuricemia is gout. However, many studies have reported that hyperuricemia also plays an important role in cardiac-kidney vascular system disease and metabolic syndrome. Hence, by defining the gravity of the condition based on the existing facts, the condition requires proper understanding followed by a strong and rational approach. The symptoms of Hyperuricemia and Gouty arthritis are similar to vatharakta, a disease explained in classical Ayurvedic textbooks. Since it is an outcome of impaired uric acid metabolism, A drug having agnideepana, amapachana, pithahara and raktaprasadana property is effective in this clinical condition. The study drug Amrita Guggulu described in Chakradatta Vatarakta chikitsa, Amritashadangam kashayam described in Chikitsamanjari Vatarakta chikitsa are widely used by Ayurvedic practitioners of kerala for treating hyperuricemia and its complications.Since the condition is having high prevalence even now, it is need of the hour to have a safe and effective treatment for the condition.Since prevention is better than cure, managing modifiable risk factors plays a key role in medical practice. Even though the incidence and prevalence of Gouty arthritis, Uric acid nephrolithiasis and Acute Uric acid nephropathies are increasing in the past two decades, the management of the risk factor is still unsatisfactory in terms of the community- wide lack of knowledge about the risk factor, availability of a cost effective and effective medicament.